SUPN - Supernus Pharma inks supply agreement with Bachem for key ingredient in ADHD drug

Supernus Pharmaceuticals (SUPN) has entered into an exclusive agreement with Bachem Americas, under which the latter will be responsible for the supply of viloxazine hydrochloride, the active pharmaceutical ingredient (“API”) of Qelbree extended-release capsules.In April, the FDA approved Qelbree for the treatment of attention-deficit hyperactivity disorder in patients aged 6 – 17 years. The commercial launch of the drug took place in the following month.Except in the case of earlier termination, the agreement with Bachem for the supply of API will run until July 2026 with an option for another two-year extension, Supernus said in a regulatory filing on Monday.Following the approval of Qelbree, Jefferies upgraded Supernus to buy from hold, citing two surveys that indicated a better-than-expected potential for ADHD therapy.

For further details see:

Supernus Pharma inks supply agreement with Bachem for key ingredient in ADHD drug